6-Chloropurine Riboside - CAS 5399-87-1
Catalog: |
BB028447 |
Product Name: |
6-Chloropurine Riboside |
CAS: |
5399-87-1 |
Synonyms: |
6-Chloro Inosine; 6-Chloro-9-(beta-D-ribofuranosyl)purine; 6-chloroinosine; 6-Chloropurine-9-β-D-ribofuranoside; 6-Chloro-6-deaminoadenosine; 6-Chloro-9-β-D-ribofuranosyl-9H-purine; 6-Chloro-9-β-D-ribofuranosylpurine; 6-Chloronebularine; 6-Chloropurine-D-riboside; 6-Chloropurinosine; 9-(β-D-Ribofuranosyl)-6-chloropurine; NSC 4910; Chloropurine riboside |
IUPAC Name: | (2R,3R,4S,5R)-2-(6-chloropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol |
Description: | 6-Chloropurine Riboside is an adenosine deaminase substrate. 6-Chloropurine Riboside is a modified nucleoside where a chlorine atom is attached to the 6-position of the purine base. It is used in biochemical research to study nucleic acid structure and function, and to investigate nucleic acid interactions. Additionally, it serves as a precursor in the synthesis of other modified nucleosides and nucleotides for therapeutic and diagnostic applications. |
Molecular Weight: | 286.67 |
Molecular Formula: | C10H11ClN4O4 |
Canonical SMILES: | C1=NC2=C(C(=N1)Cl)N=CN2C3C(C(C(O3)CO)O)O |
InChI: | InChI=1S/C10H11ClN4O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2/t4-,6-,7-,10-/m1/s1 |
InChI Key: | XHRJGHCQQPETRH-KQYNXXCUSA-N |
Boiling Point: | 614.8±65.0 °C at 760 mmHg |
Melting Point: | 180-182 °C |
Purity: | ≥98% by HPLC |
Density: | 2.03±0.1 g/cm3 |
Solubility: | Soluble in DMSO (Sparingly, Heated), Methanol (Slightly, Heated), Water (Slightly, Heated) |
Appearance: | White to beige solid |
Storage: | Store at -20 °C |
LogP: | -0.90880 |
GHS Hazard Statement: | H302 (50%): Harmful if swallowed [Warning Acute toxicity, oral] |
Precautionary Statement: | P261, P264, P270, P271, P280, P301+P312, P302+P352, P304+P312, P304+P340, P305+P351+P338, P312, P321, P322, P330, P332+P313, P337+P313, P362, P363, P403+P233, P405, and P501 |
Signal Word: | Warning |
Publication Number | Title | Priority Date |
WO-2021203043-A2 | Targeted inhibition using engineered oligonucleotides | 20200402 |
US-11007134-B1 | Ceramide containing capsules, ceramide compositions, and cosmetic compositions thereof | 20200331 |
WO-2021202493-A1 | Ceramide containing capsules, ceramide compositions, and cosmetic compositions thereof | 20200331 |
WO-2021152146-A1 | Process for the production of closed linear dna | 20200131 |
WO-2021152147-A1 | Closed linear dna with modified nucleotides | 20200131 |
PMID | Publication Date | Title | Journal |
22959520 | 20121001 | Biosynthesis of anti-HCV compounds using thermophilic microorganisms | Bioorganic & medicinal chemistry letters |
22356237 | 20120101 | Synthesis of 2'-substituted inosine analogs via unusual masking of the 6-hydroxyl group | Nucleosides, nucleotides & nucleic acids |
19514790 | 20090618 | Suzuki-miyaura and sonogashira coupling of 6-chloropurines and -nucleosides in water | Organic letters |
17766124 | 20071115 | 5'-O-masked 2'-deoxyadenosine analogues as lead compounds for hepatitis C virus (HCV) therapeutic agents | Bioorganic & medicinal chemistry |
17418578 | 20070601 | Preparation, biological activity and endogenous occurrence of N6-benzyladenosines | Bioorganic & medicinal chemistry |
Complexity: | 339 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 4 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 286.0468825 |
Formal Charge: | 0 |
Heavy Atom Count: | 19 |
Hydrogen Bond Acceptor Count: | 7 |
Hydrogen Bond Donor Count: | 3 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 286.0468825 |
Rotatable Bond Count: | 2 |
Topological Polar Surface Area: | 114 Å2 |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | 0.3 |
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Purines
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS